Remdesivir not checked

Gilead (Kite) · GS-5734

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
None yet
 
Trials
4 active
8 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA class
Tested for
COVID-19 (4 trials)
Main trialPhase 3
“The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.”In the company’s words, NCT04292730 on ClinicalTrials.gov
Other names
GS-5734 · Veklury

Other drugs for COVID-19

All 43 drugs for COVID-19

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Completed 29 Apr 2020 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Phase 3Terminated 20 Apr 2022 Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
Phase 2/3Completed 10 Feb 2023 Study of Remdesivir in Participants Below 18 Years Old With COVID-19
Phase 1/2Completed 26 Feb 2021 Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
Phase 2Authorised not given OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study
Phase 2Authorised not given SAFETY AND EFFICACY OF A 10-DAY COURSE OF REMDESIVIR TO PREVENT SEVERE COVID-19 IN ASYMPTOMATIC OR PAUCISYMPTOMATIC SARS-COV-2-POSITIVE KIDNEY TRANSPLANT RECIPIENTS: A SINGLE-ARM PROOF-OF-CONCEPT INTERVENTIONAL TRIAL
Phase 2Authorised not given Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) – A phase 2 proof-of-concept, national, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy of remdesivir in adult patients hospitalized for TBE
Phase 2Authorised not given Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Remdesivir

Following is part of Solo: you see every change to Remdesivir the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in